SlideShare uses cookies to improve functionality and performance, and to provide you with relevant advertising. If you continue browsing the site, you agree to the use of cookies on this website. See our User Agreement and Privacy Policy.
SlideShare uses cookies to improve functionality and performance, and to provide you with relevant advertising. If you continue browsing the site, you agree to the use of cookies on this website. See our Privacy Policy and User Agreement for details.
Successfully reported this slideshow.
Activate your 14 day free trial to unlock unlimited reading.
1.
GUILLAIN
BARRE
SYNDROME
MOHD SAQUIB KHAN
M.Sc 3rd SEMESTER
DEPARTMENT OF BIOCHEMISTRY &
MOLECULAR BIOLOGY
PONDICHERRY UNIVERSITY
2.
INTRODUCTION
o Popularly known as “French polio” is an acute inflammatory
demyelinating polyneuropathy characterized by progressive
muscle weakness and areflexia.
o All forms of Guillain–Barré syndrome are autoimmune disease,
due to an immune response to foreign antigens.
o It has an annual incidence of 0.6 to 2.4 cases per 100,000
population and occurs at all ages and in both sexes.
o With the marked decline in the incidence of polio, GuillainBarré syndrome is now the most common cause of acute
flaccid paralysis in healthy people.
3.
TYPES
o ACUTE INFLAMMATORY
DEMYELINATING POLYNEUROPATHY(AIDP)- autoimmune
response directed against Schwann cell membranes.
o MILLER FISHER SYNDROME (MFS)- Anti-GQ1b antibodies
are present in 90% of cases.
o ACUTE MOTOR AXONAL NEUROPATHY (AMAN) also
known as Chinese paralytic syndrome- Anti-GD3 antibodies
are found more frequently in AMAN.
o ACUTE PANAUTONOMIC NEUROPATHY- associated with a
high mortality rate, owing to cardiovascular involvement, and
associated dysrhythmias.
4.
CAMPYLOBACTER
INFECTION
o Campylobacter infection is the most commonly identified
precipitant of Guillain-Barré syndrome.
o A case-control study involving 103 patients with the
disease found that 26% of affected individuals had
evidence of recent C. jejuni infection compared with 2%
of household and 1% of age-matched controls.
o Seventy percent of those infected with C. jejuni reported
a diarrheal illness within 12 weeks before the onset of
the neurologic illness.
5.
o The main lesions are acute inflammatory demyelinating
neuropathy and, particularly in patients with
Campylobacter-associated disease, acute axonal
degeneration.
o These changes may be caused by cross-reacting
antibodies to GM1 ganglioside (present in high
concentrations in peripheral nerve myelin) formed in
response to similar epitopes expressed by the infecting
Campylobacter strain.
o However, mechanisms other than molecular mimicry
may be associated with the production of antibodies to
GM1 ganglioside.
6.
ANTIBODIES AGAINST
GANGLIOSIDES
o Anti-GD3-Anti-GD3 antibodies have been found in
association with specific forms of Guillain-Barré
syndrome.
o In vivo studies of isolated anti-GM1 and GD3
antibodies indicate the antibodies can interfere with
motor neuron function.
o Anti-GD1a antibodies were highly associated acute
motor axonal neuropathy while high titers of anti-GM1
were more frequent indicating that GD1a possibly
targets the axolemma and nodes of ranvier. .
7.
o Anti-GM1-Levels of anti-GM1 are elevated in
patients with various forms of dementia &
correlate with more severe Guillain-Barré
syndrome.
o Titers to GM1 in other diseases (rheumatoid
arthritis, primary Sjögren's syndrome and
systemic lupus erythematosus) was also
elevated.
o The autoimmune role of anti-GM1 is still unclear.
8.
o Anti-GQ1-Anti-GQ1b are found in MillerFisher syndrome.
o Studies of these antibodies reveal large
disruption of the Schwann cells.
o Anti-GQ1b IgG levels were elevated in
patients with ophthalmoplegia in GuillainBarré syndrome.
9.
PATHOGENESIS
o In Guillain-Barré syndrome, the myelin sheath
surrounding the axon is lost.
o Demyelination is a common response of neural
tissue to many agents and conditions, including
physical trauma, hypoxemia, toxic chemicals,
vascular insufficiency, and immunological
reactions.
o Loss of the myelin sheath in Guillain-Barré
syndrome makes nerve impulse transmission is
aborted.
10.
CLINICAL MANIFESTATION
o The syndrome may develop rapidly over the course
of hours or days, or may take up to 3 to 4 weeks to
develop.
o Most patients demonstrate the greatest weakness
in the first weeks of the disorder.
o Patients are at their weakest point by the third
week of the illness.
o In the beginning, a flaccid, ascending paralysis
develops quickly.
11.
o The patient may first notice weakness in the
lower extremities that may quickly extend to
include weakness and abnormal sensations in
the arms.
o Deep tendon reflexes are usually lost, even in
the earliest stages.
o The trunk and cranial nerves may become
involved.
o Respiratory muscles can become affected,
resulting in respiratory compromise.
12.
DIAGNOSIS
o The history of the onset of symptoms can be
revealing because symptoms of Guillain-Barré
syndrome usually begin with weakness or
paresthesias of the lower extremities and
ascend in a symmetrical pattern.
o A lumbar puncture may be performed and reveal
increased protein.
o Also, nerve conduction studies record impulse
transmission along the nerve fiber.
13.
TREATMENT
o The main modalities of therapy for Guillain-Barré
syndrome include
– Plasmapheresis
– Administration of intravenous immune globulin
o The first therapy proven to benefit patients with
Guillain-Barré syndrome is plasmapheresis.
o This procedure mechanically removes humoral
factors.
14.
o Plasma exchange is recommended for patients
who
– Are unable to walk unaided
– Demonstrate worsening vital capacities
– Require mechanical ventilation
– Have significant bulbar weakness
o Intravenous immunoglobulin (IVIG) is also useful
in managing Guillain-Barré syndrome.
15.
REFERENCE
o Davids, H. "Guillain-Barre Syndrome".
Medscape Reference. Retrieved 3 Jan 2012.
o Jump up Mori, M; Kuwabara, S; Fukutake, T;
Hattori, T (2002). "Plasmapheresis and Miller
Fisher syndrome: analysis of 50 consecutive
cases". Journal of neurology, neurosurgery, and
psychiatry 72 (5).
o Thomas J.Kindt,Barabara A.Osborne,Richard
A.Goldsby.Kuby Immunology 6th edition.
16.
American actor
Andy Griffith
developed GuillainBarré syndrome in
1983. Griffith is seen
here receiving an
award at the White
House in 2005.